A top executive at a biotechnology company that sequences virus variants said Sunday the United States is in a better position tracking COVID-19 variants, but still has “blind spots” around the country.
In an interview on CBS News’ “Face The Nation,” Francis deSouza, CEO of the biotechnology company Illumina, said the U.K. has been “one of the leaders in terms of rolling out a global immunology structure” for COVID.
“We’re in a lot different position than we were at the beginning of the pandemic,” he said. “Certainly a year ago we were sequencing very little, in terms of the positives we were seeing in this country. But over the last year, we started to see sequencing infrastructure being rolled out. “
Read more at Newsmax© 2021 Newsmax. All rights reserved.